Aehr Test Systems
AEHR
$94.69
+0.94%
Aehr Test Systems designs, manufactures, and sells advanced test and burn-in systems for logic, optical, and memory integrated circuits, primarily serving the semiconductor manufacturing industry. The company is a niche player specializing in wafer-level burn-in and test solutions, with a strong focus on the automotive and mobility IC markets, and has recently pivoted toward AI processor testing. The current investor narrative centers on Aehr's strategic shift from electric vehicle (EV) applications to AI-driven semiconductor testing, which has driven record bookings and a surge in stock price, with revenue expected to triple next year. The company's role in the AI infrastructure build-out, particularly for power components and specialized test equipment, has become a key catalyst, though its small size and high volatility remain points of debate.…
AEHR
Aehr Test Systems
$94.69
Related headlines
Investment Opinion: Should I buy AEHR Today?
Rating: Hold. AEHR is a high-growth, high-risk stock that is best suited for investors with a high risk tolerance. The analyst consensus is mixed, with an average target price of $130, implying a 50.7% upside from the current price of $86.26. However, the wide range of targets ($110-$175) and the limited coverage (4 analysts) suggest significant uncertainty. The core thesis is that AEHR is well-positioned to benefit from the AI infrastructure build-out, but the valuation is already pricing in much of this growth.
Sign up to view all
AEHR 12-Month Price Forecast
The AI assessment is cautiously bullish. The company's pivot to AI testing is well-timed, and the record bookings suggest strong demand. However, the valuation is stretched, and the company has yet to prove it can generate consistent profits. The high beta and negative TTM earnings add to the risk. I would upgrade my stance to more bullish if the company shows sustained profitability and revenue growth above 50% for the next two quarters. I would downgrade to neutral if bookings decline or if the stock's PS ratio exceeds 70x without corresponding growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $128.00 and implied upside of +35.2% versus the current price.
Average Target
$128.00
0 analysts
Implied Upside
+35.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$110 - $175
Analyst target range
The wide spread between the low and high targets ($110 to $175) indicates significant uncertainty about Aehr's future, likely due to the volatility of its end markets and the execution risk associated with its AI pivot. The high target of $175 assumes that the company will successfully capitalize on the AI infrastructure boom, with revenue tripling and margins expanding, while the low target of $110 may price in a more moderate growth scenario or potential competitive pressures. Recent ratings actions show a mixed picture: William Blair upgraded from Market Perform to Outperform in March 2026, while Craig-Hallum downgraded from Buy to Hold in March 2024, and Freedom Broker has maintained Hold ratings throughout 2026. This pattern suggests that while some analysts see upside, others remain cautious, and the limited coverage (only 4 analysts) means the stock may be under-researched, leading to less efficient price discovery and higher volatility.
Bulls vs Bears: AEHR Investment Factors
AEHR presents a classic high-risk, high-reward scenario. The bull case is compelling: record bookings, a strategic pivot to AI testing, and explosive Q4 growth suggest the company is riding a powerful secular wave. However, the bear case is equally strong: the stock trades at an astronomical 56.6x sales, profitability is inconsistent, and the high beta (3.07) exposes investors to severe drawdowns. The most important tension is whether the AI-driven revenue surge can be sustained and translated into durable profits. If revenue triples as expected and margins expand, the stock could justify its valuation; if growth disappoints or competition intensifies, the stock could fall sharply. Currently, the evidence slightly favors the bull case given the record bookings and revenue inflection, but the valuation leaves no margin for error.
Bullish
- Explosive Revenue Growth in Q4 FY2026: Q4 FY2026 revenue surged 40.19% YoY to $19.75M, a sharp acceleration from the prior three quarters which averaged ~$10.4M. This inflection signals strong demand for AI-related test systems and validates the strategic pivot.
- Record Bookings Signal Future Demand: Q3 FY2026 bookings hit a record $37.2M, nearly 3.6x the quarter's revenue of $10.31M. This backlog provides strong visibility into near-term revenue and supports the expectation of revenue tripling next year.
- Massive 1-Year Stock Appreciation: AEHR stock surged 228.1% over the past year, vastly outperforming the S&P 500's 18.65% gain. This reflects strong market conviction in the AI-driven growth narrative and has created substantial shareholder value.
- Strategic AI Pivot with Major Orders: The company secured a large AI chip testing order in March 2026, which drove an 18% single-day surge. This validates its critical role in the AI infrastructure supply chain and opens a potentially large new market.
Bearish
- Extreme Valuation with PS Ratio of 56.6x: At $86.26, the price-to-sales ratio is 56.6x, an extraordinarily high multiple even for high-growth tech. This implies the market is pricing in flawless execution and sustained hyper-growth, leaving little room for disappointment.
- Inconsistent Profitability and Negative Margins: TTM net income is negative (EPS -$0.0025), with operating margin at -28.3% and net margin at -14.3%. While Q4 showed a profit, the company has struggled to achieve consistent profitability, raising concerns about earnings quality.
- High Volatility and Beta of 3.07: With a beta of 3.07, AEHR is highly sensitive to market swings. The stock has experienced a max drawdown of -47.62% and a 1-month decline of -12.67%, indicating significant downside risk for investors.
- Analyst Coverage Sparse and Mixed: Only 4 analysts cover the stock, with a wide target range of $110-$175. Recent actions include a downgrade by Craig-Hallum (Buy to Hold) and a Hold from Freedom Broker, suggesting uncertainty about the growth trajectory.
AEHR Technical Analysis
Aehr Test Systems is in a powerful long-term uptrend, with the stock up 228.1% over the past year, dramatically outperforming the S&P 500's 18.65% gain. The current price of $86.26 sits at 52.6% of its 52-week range (between $18.70 low and $147.40 high), indicating the stock has pulled back significantly from its highs but remains well above its lows. This positioning suggests a consolidation phase after a massive rally, with the stock trading roughly midway between support and resistance, reflecting a market that is reassessing the sustainability of the AI-driven growth story.
Beta
3.07
3.07x market volatility
Max Drawdown
-47.6%
Largest decline past year
52-Week Range
$19-$147
Price range past year
Annual Return
+256.4%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | -26.7% | -1.1% |
| 3m | -12.7% | +3.0% |
| 6m | +165.5% | +15.4% |
| 1y | +256.4% | +16.2% |
| ytd | +327.3% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Aehr's revenue trajectory has been volatile but recently showed strong growth, with the latest quarter (Q4 FY2026, ending May 29, 2026) reporting revenue of $19.75 million, a 40.19% year-over-year increase. However, this follows a period of declining revenue: Q1 FY2026 revenue was $10.97 million, Q2 was $9.88 million, and Q3 was $10.31 million, indicating a sharp sequential acceleration in Q4. The revenue segments show Systems contributing $6.76 million, Contactors $2.61 million, and Services $1.59 million, with Systems being the primary driver. This growth inflection is tied to the AI pivot, with record bookings of $37.2 million in Q3, suggesting momentum may continue, but the multi-quarter trend has been uneven, reflecting the lumpy nature of capital equipment sales.
Quarterly Revenue
$19751000.0B
2026-05
Revenue YoY Growth
+40.2%
YoY Comparison
Gross Margin
40.6%
Latest Quarter
Free Cash Flow
$-5376000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Given that Aehr's trailing twelve-month net income is negative (EPS of -$0.0025), the price-to-sales (PS) ratio is the most appropriate valuation metric, as PE is not meaningful. The current PS ratio is 56.63x, which is extremely high, reflecting the market's expectation of substantial future growth. The forward PE of 62.36x, based on estimated EPS of $2.27, implies that analysts expect a dramatic earnings recovery, but even on that basis, the stock is not cheap. The gap between the negative trailing EPS and the positive forward EPS indicates the market is pricing in a significant inflection in profitability, which is a high-risk assumption.
PE
-401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-232.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The company's negative TTM net income (EPS -$0.0025) and operating margin of -28.3% indicate that profitability is not yet established. While Q4 FY2026 showed a net income of $1.39M, this was a single quarter and may not be sustainable. The company's free cash flow is also negative at -$5.38M TTM, meaning it is burning cash. However, the balance sheet is strong with a current ratio of 10.33 and minimal debt (D/E 0.045), providing a buffer. Revenue is highly concentrated in a few large orders, as evidenced by the lumpy quarterly pattern, which creates earnings volatility and makes forecasting difficult. The reliance on the AI sector for growth also introduces concentration risk if AI capex slows.
FAQ
The key risks are: 1) Financial risk: The company has negative TTM net income and free cash flow, though it has a strong balance sheet with low debt. 2) Market risk: The stock is highly volatile with a beta of 3.07, and a broad tech selloff could hit it hard. 3) Competitive risk: Larger competitors like Teradyne and Advantest could erode market share. 4) Company-specific risk: Revenue is concentrated in a few large orders, and any cancellation could significantly impact results. The most severe risk is a failure to sustain the AI-driven growth, which could lead to a de-rating and a potential decline to the 52-week low of $18.70, a -78% drop from current levels.
The 12-month forecast is uncertain, with a wide range of outcomes. In the bull case (30% probability), the stock could reach $130-$175, driven by strong AI demand and revenue growth. In the base case (50% probability), the stock is likely to trade around $110-$130, in line with the analyst average target. In the bear case (20% probability), the stock could fall to $50-$80 if growth disappoints or the market de-rates. The most likely scenario is the base case, assuming the company continues to execute on its AI pivot and delivers on its growth targets. Investors should monitor quarterly earnings and bookings for signs of momentum.
AEHR is significantly overvalued based on traditional metrics. The PS ratio of 56.6x is extremely high, even for a high-growth company. The forward PE of 62.36x, based on estimated EPS of $2.27, also indicates a premium valuation. Compared to the semiconductor industry average PS ratio of around 5-10x, AEHR trades at a massive premium. This valuation implies the market expects revenue to triple and margins to expand dramatically. If the company fails to meet these expectations, the stock could de-rate sharply. However, if the AI-driven growth materializes as expected, the premium may be justified. Investors are paying for future growth, not current fundamentals.
AEHR is a high-risk, high-reward stock. The analyst average target of $130 implies a 50.7% upside from the current price of $86.26, but the stock is extremely volatile with a beta of 3.07. The company is growing rapidly, with Q4 revenue up 40.19% YoY and record bookings of $37.2M, but it is not yet consistently profitable. The PS ratio of 56.6x is very high, meaning the stock is priced for perfection. It could be a good buy for investors who believe in the AI-driven growth story and can tolerate significant drawdowns, but it is not suitable for risk-averse investors. A more prudent approach would be to wait for a pullback to a lower valuation or for evidence of sustained profitability.
AEHR is more suitable for long-term investors with a high risk tolerance, given its high volatility and growth stage. The stock has a beta of 3.07, meaning it can swing wildly in the short term, making it risky for short-term traders. The company is in a growth phase, with revenue expected to triple next year, so a long-term horizon of at least 3-5 years would allow the investment thesis to play out. Short-term trading could be profitable but requires precise timing and risk management. The company does not pay a dividend, so returns are entirely dependent on capital appreciation. Investors should be prepared for significant drawdowns, as seen in the -47.62% max drawdown, and should only invest money they can afford to lose.